The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $14.60 in the prior trading day, Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $14.30, down -2.05%. In other words, the price has decreased by $-2.05 from its previous closing price. On the day, 0.81 million shares were traded. VRDN stock price reached its highest trading level at $14.74 during the session, while it also had its lowest trading level at $14.0.
Ratios:
Our goal is to gain a better understanding of VRDN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.26 and its Current Ratio is at 18.26. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On June 14, 2023, BTIG Research started tracking the stock assigning a Buy rating and target price of $46.
On May 30, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $44.RBC Capital Mkts initiated its Outperform rating on May 30, 2023, with a $44 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 22 ’24 when Fairmount Funds Management LLC bought 476,190 shares for $21.00 per share. The transaction valued at 9,999,990 led to the insider holds 1,839,954 shares of the business.
Meisner Lara sold 27 shares of VRDN for $765 on Jun 16 ’23. The Chief Legal Officer now owns 29,971 shares after completing the transaction at $28.35 per share. On Jun 15 ’23, another insider, Meisner Lara, who serves as the Chief Legal Officer of the company, sold 2,269 shares for $28.02 each. As a result, the insider received 63,577 and left with 29,971 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 897576704 and an Enterprise Value of 667589504. For the stock, the TTM Price-to-Sale (P/S) ratio is 2895.52 while its Price-to-Book (P/B) ratio in mrq is 3.28. Its current Enterprise Value per Revenue stands at 2126.081 whereas that against EBITDA is -2.629.
Stock Price History:
Over the past 52 weeks, VRDN has reached a high of $30.30, while it has fallen to a 52-week low of $10.93. The 50-Day Moving Average of the stock is -19.27%, while the 200-Day Moving Average is calculated to be -19.89%.
Shares Statistics:
The stock has traded on average 914.95K shares per day over the past 3-months and 797540 shares per day over the last 10 days, according to various share statistics. A total of 62.77M shares are outstanding, with a floating share count of 55.85M. Insiders hold about 11.02% of the company’s shares, while institutions hold 90.30% stake in the company. Shares short for VRDN as of 1711584000 were 9471425 with a Short Ratio of 10.35, compared to 1709164800 on 7574402. Therefore, it implies a Short% of Shares Outstanding of 9471425 and a Short% of Float of 15.43.
Earnings Estimates
A comprehensive evaluation of Viridian Therapeutics Inc (VRDN) is underway, with the input of VeriSign, Inc. analysts contributing to its current rating.The consensus estimate for the next quarter is $14.30, with high estimates of $0.16 and low estimates of $29.92.
